Equillium (0A4D) Price & Analysis

2 Followers

0A4D Stock Chart & Stats

$2.26

-$0.12(-5.00%)

At close: Jul 31 4:00 PM EDT

$2.26

-$0.12(-5.00%)

Day’s Range― - ―

52-Week Range$0.83 - $3.53

Previous CloseN/A

Volume1.91K

Average Volume (3M)3.70K

Market Cap

$129.99M

Enterprise Value$301.20

Total Cash (Recent Filing)$57.16M

Total Debt (Recent Filing)$584.00K

Price to Earnings (P/E)―

Beta0.15

Next Earnings

Nov 18, 2026

EPS Estimate

-0.05

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.26

Shares Outstanding63,408,080

10 Day Avg. Volume1,737

30 Day Avg. Volume3,704

Financial Highlights & Ratios

PEG Ratio-0.06

Price to Book (P/B)4.98

Price to Sales (P/S)0.00

P/FCF Ratio-6.25

Enterprise Value/Market Cap<0.01

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit>-0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$11.60

Price Target Upside413.27% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-0.23

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low LeverageVery low debt relative to equity gives Equillium a comparatively conservative capital structure and reduces near-term interest and refinancing pressure. This financial flexibility can help preserve resources for clinical development, although it does not eliminate the need to fund ongoing operating losses.

Focused Immunology PipelineA focused strategy in severe autoimmune and inflammatory diseases provides clear therapeutic direction and concentrates limited resources on areas where targeted immune modulation may address substantial unmet need. This specialization can support coherent development priorities across multiple clinical programs.

Multiple Development AssetsHaving a lead biologic alongside EQ101 and additional preclinical assets creates more than one potential development path. A broader pipeline can improve the possibility that progress in one program offsets setbacks elsewhere, while extending the company’s long-term platform opportunity.

Bears Say

No Current RevenueZero trailing revenue combined with a sizable net loss shows that Equillium has not yet established an operating revenue base. Until a program generates commercial or collaboration income, financial performance will remain dependent on development progress and access to outside funding.

Persistent Cash BurnSustained operating and free-cash-flow losses of roughly $20 million annually require continued financing to maintain research and clinical activities. This dependence can constrain strategic flexibility and make future funding availability important to the company’s ability to advance its pipeline.

Ongoing Equity ErosionNegative return on equity indicates that the company is consuming shareholder capital rather than generating returns from it. If losses continue, book equity may decline despite low debt, weakening the balance-sheet cushion available to support long-duration clinical development.

Equillium News

Equillium management to meet with Piper Sandler

Meeting to be held on September 8 hosted by Piper Sandler. Published first on TheFly – the ultimate...

13d ago

Equillium reports Q2 EPS (4c), consensus (6c)

“We continue to make meaningful progress advancing EQ504 toward the clinic,” said Bruce Steel, Chief Executive Officer of...

1M ago

Equillium (EQ) Q2 Earnings Cheat Sheet

Equillium (EQ) is scheduled to report 2nd quarter earnings on 08/12/2026. Regarding Q2 estimates, Wall Street analysts expect...

1M ago

Equillium initiated with a Buy at Clear Street

Clear Street analyst Kaveri Pohlman initiated coverage of Equillium (EQ) with a Buy rating and $9 price target...

2M ago

Equillium initiated with an Overweight at Piper Sandler

Piper Sandler analyst Yasmeen Rahimi initiated coverage of Equillium (EQ) with an Overweight rating and $20 price target...

2M ago

Equillium Shareholders Approve Reverse Split and Capital Changes

Equillium ( ($EQ) ) has shared an announcement. On May 28, 2026, Equillium, Inc. held its 2026 annual...

4M ago

Equillium price target raised to $7 from $6 at Raymond James

Raymond James raised the firm’s price target on Equillium (EQ) to $7 from $6 and keeps a Strong...

4M ago

Leerink upgrades Equillium on ‘supportive’ ulcerative colitis data

Leerink upgraded Equillium (EQ) to Outperform from Market Perform with a price target of $6, up from $1....

4M ago

Equillium upgraded to Outperform from Market Perform at Leerink

Leerink upgraded Equillium (EQ) to Outperform from Market Perform with a $6 price target Published first on TheFly...

4M ago

Equillium: Compliance, Operational and Market Risks Cloud Long-Term Outlook for Shareholders

Equillium (EQ) has disclosed a new risk, in the Regulation category. Equillium faces ongoing exposure to U.S. public...

4M ago

Equillium reports Q1 EPS (6c), consensus (4c)

“Following our March year-end update and financing, we have remained focused on advancing EQ504 toward the clinic while...

4M ago

Equillium appoints Snehal Naik as chief development officer

Equillium (EQ) appointed Snehal Naik as chief development officer. Naik will lead clinical development and medical strategy across...

4M ago

Equillium initiated with an Outperform at Oppenheimer

Oppenheimer initiated coverage of Equillium (EQ) with an Outperform rating and $7 price target The firm is positive...

5M ago

EQ Upcoming Earnings Report: What to Expect?

Equillium (EQ) is scheduled to report 4th quarter earnings on 03/26/2026. Regarding Q4 estimates, Wall Street analysts expect...

6M ago

0A4D FAQ

What was Equillium Inc’s price range in the past 12 months?

Equillium Inc lowest share price was $0.83 and its highest was $3.53 in the past 12 months.

What is Equillium Inc’s market cap?

Equillium Inc’s market cap is $129.99M.

When is Equillium Inc’s upcoming earnings report date?

Equillium Inc’s upcoming earnings report date is Nov 18, 2026 which is in 61 days.

How were Equillium Inc’s earnings last quarter?

Equillium Inc released its earnings results on Aug 13, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.054 by $0.014.

Is Equillium Inc overvalued?

According to Wall Street analysts Equillium Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Equillium Inc pay dividends?

Equillium Inc does not currently pay dividends.

What is Equillium Inc’s EPS estimate?

Equillium Inc’s EPS estimate is -0.05.

How many shares outstanding does Equillium Inc have?

Equillium Inc has 63,408,080 shares outstanding.

What happened to Equillium Inc’s price movement after its last earnings report?

Equillium Inc reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.054. Following the earnings report the stock price went up 6.573%.

Which hedge fund is a major shareholder of Equillium Inc?

Currently, no hedge funds are holding shares in GB:0A4D

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Equillium Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

373.15%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Equillium Inc

Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.

Equillium (0A4D) Earnings & Revenues

Historic Earnings Reports

0A4D Stock 12 Month Forecast

Average Price Target

$11.60

▲(413.27% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","21":"$21","-1":"-$1","4.5":"$4.5","15.5":"$15.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,4.5,10,15.5,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.202,3.571076923076923,4.940153846153846,6.30923076923077,7.678307692307693,9.047384615384615,10.41646153846154,11.785538461538463,13.154615384615386,14.52369230769231,15.892769230769233,17.261846153846157,18.630923076923082,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.202,2.924923076923077,3.647846153846154,4.3707692307692305,5.093692307692308,5.8166153846153845,6.539538461538461,7.2624615384615385,7.985384615384615,8.708307692307692,9.431230769230769,10.154153846153847,10.877076923076922,{"y":11.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.202,2.571076923076923,2.940153846153846,3.309230769230769,3.6783076923076923,4.047384615384615,4.416461538461538,4.7855384615384615,5.154615384615385,5.523692307692308,5.892769230769231,6.261846153846154,6.630923076923077,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.64,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.475,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.425,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.901,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.525,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.548,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.78,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.04,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.07,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.91,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.12,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.28,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.202,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >